Sanofi to acquire Ablynx for €3.9 Billion

Sanofi (NYSE: SNY) and Ablynx (EBR:ABLX), a biopharmaceutical company engaged in the discovery and development of Nanobodies^®, entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9 billion ($4.8 billion in USD).
As quoted in the press release:

Sanofi’s Chief Executive Officer Olivier Brandicourt commented, “With Ablynx, we continue to advance the strategic transformation of our Research and Development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders. This acquisition builds on a successful existing partnership. We are also pleased to reaffirm our commitment to Belgium, where we have invested significantly over the years in our state-of-the-art biologics manufacturing facility in Geel. We intend to maintain and support the Ablynx science center in Ghent.”

Click here to read the full press release.